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Abstract
Background Frailty and adverse drug effects are linked in the fact that polypharmacy is correlated with the severity of frailty;
however, a causal relation has not been proven in older people with clinically manifest frailty.
Methods A literature search was performed in Medline to detect prospective randomized controlled trials (RCTs) testing the
effects of pharmacological interventions or medication optimization in older frail adults on comprehensive frailty scores or partial
aspects of frailty that were published from January 1998 to October 2019.
Results Twenty-five studies were identified, 4 on comprehensive frailty scores and 21 on aspects of frailty. Two trials on
comprehensive frailty scores showed positive results on frailty although the contribution of medication review in a multidimen-
sional approach was unclear. In the studies on aspects related to frailty, ten individual drug interventions showed improvement in
physical performance, muscle strength or body composition utilizing alfacalcidol, teriparatide, piroxicam, testosterone, recom-
binant human chorionic gonadotropin, or capromorelin. There were no studies examining negative effects of drugs on frailty.
Conclusion So far, data on a causal relationship between drugs and frailty are inconclusive or related to single-drug interventions
on partial aspects of frailty. There is a clear need for RCTs on this topic that should be based on a comprehensive, internationally
consistent and thus reproducible concept of frailty assessment.
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Introduction
Frailty has been defined by the World Health Organization as
a ‘progressive age-related decline in physiological systems
that results in decreased reserves of intrinsic capacity, which
confers extreme vulnerability to stressors and increases the
risk of a range of adverse health outcomes’ [1, 2]. While there
is still some debate concerning a more precise definition of
frailty, this widely recognized definition of frailty was also
implemented by the first joint action (JA) on the prevention
of frailty, ADVANTAGE [1, 2]. The prevalence of frailty
increases with age (about 11% in community-dwelling older
adults [3–6]); frailty is a dynamic process and older people are
commonly staged as being robust/non-frail, prefrail, or frail
[3, 5]. The presence of frailty in older adults has been associ-
ated with serious adverse clinical outcomes including, falls,
disability, hospitalization, nursing home admissions, and even
mortality [3, 4, 7].
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There are many instruments designed to define and measure
frailty or different aspects of frailty including its physical, cog-
nitive, social, environmental, and emotional domains [8, 9]. The
most commonly used instruments are the frailty phenotype and
the Frailty Index [10]. However, according to the
ADVANTAGE JA initiative, validated instruments such as the
Short Physical Performance Battery (SPPB), the Edmonton Frail
Scale, (The Rockwood) Clinical frailty Scale, or PRISMA-7
which do not require special equipment and take less than
10min to complete are useful for frailty screening and preferable
to others across clinical settings [1, 2].
In a previous publication examining the association of
polypharmacy (i.e., often defined as ≥ 5 daily medications)
and hyperpolypharmacy (i.e., ≥ 10 daily medications) with
frailty, we found that polypharmacy is common in prefrail
and frail adults and that robust/non-frail persons with
polypharmacy are at significantly higher odds for developing
prefrailty compared to those not exposed to polypharmacy [5].
This association between polypharmacy, inappropriate pre-
scribing, and frailty has been corroborated by several system-
atic reviews that suggest, but do not prove, that a reduction of
polypharmacy may prevent or improve frailty or aspects of
frailty [11–13]. In this context, an important limitation of
interpreting evidence from observational studies on medica-
tions and frailty has to be noted: clinicians often selectively
discontinue/de-prescribe in those who are frailest, thereby cre-
ating a bias regarding applicability to frail people at large. As
these associations do not provide insights on the causal rela-
tionship between medications and frailty, more research is
required to address this interaction that could reflect medica-
tions being increased to cope with frailty or frailty as a conse-
quence of medications. A lack of evidence on pharmacologi-
cal interventions for the management of frailty has been an-
ticipated, and already been indicated in literature [14–16].
Therefore, a systematic review was performed to identify ev-
idence on pharmacological interventions and frailty or aspects
of frailty from randomized controlled trials (RCT).
Approaches to tackle polypharmacy and inappropriate drug
treatment (medication optimization), as well as single-drug
interventions (pharmacological interventions) aimed at im-
proving clinically manifest frailty as a primary or secondary
outcome, were searched for by addressing both key aspects of
medication-frailty interactions: aggravating or improving
frailty through medication.
Methods
This systematic review was performed according to the meth-
odological manuals of the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA [17]).
The PRISMA checklist and PICOs are provided in
Supplementary data 1 & 2. It was an initiative of the
European Geriatric Medicine Society (EuGMS) special inter-
est group (SIG) on Pharmacology.
Search strategy
Search terms were proposed by two authors (FP and MW) to
all EuGMS Pharmacology special interest group members for
discussion and amendment. The resultant search terms
(Supplementary Material 3), combinations, and limitations
were developed and used to search MEDLINE, from
January 1998 up to and including 14th October 2019. The
key themes in our search were frailty and medicines (includ-
ing polypharmacy and inappropriate prescribing), and only
randomized controlled trials (RCT) were included.
Inclusion criteria
Publications describing the impact of medication optimization
or single-drug interventions on frailty or aspects of frailty in
older adults (≥ 60 years old, except one study [18]), evaluated
through a randomized controlled trial were examined. A broad
definition of medication optimization was used including not
only medication review, but also educational interventions,
care coordination, use of technology, or ‘brown bag’ analyses.
Exclusion criteria
Studies concerning non-geriatric or non-frail (at baseline) pa-
tients were excluded, as were studies without measurement of
frailty or aspects of frailty, or studies measuring quality of life
without providing a separate analysis of the intervention on
the aforementioned aspects of frailty. These exclusion criteria
also applied to nursing homes, though a considerable rate of
frail patients is to be expected there, but the measurement of
interventional improvements is not possible without baseline
data on frailty. Studies focusing on treatment of diseases such
as most oncology trials, association studies, or studies without
differences in medications between the control and interven-
tion group were also excluded (Fig. 1). There were no exclu-
sions regarding the language.
Study selection
The search results were exported by FP from PubMed to a
Word file (Microsoft, Redmond, Washington). Subsequently,
two reviewers (FP,MW) independently screened the titles and
abstracts of the manuscripts to identify relevant publications
describing the impact of medication optimization or drug
treatment on frailty or aspects of frailty in randomized con-
trolled trials. Each record generating uncertainty regarding
inclusion or exclusion criteria was discussed by FP and MW
in order to reach consensus about inclusion.
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Data extraction and synthesis
The following data were extracted from the selected
publications: PubMed ID (PMID), first author, publica-
tion year, type of population, mean age of study partic-
ipants and standard deviation if provided, number of
study participants, female gender, outcome relating to
a common frailty score/instrument, outcome(s) relating
to partial aspects of frailty, short description of the in-
tervention and its duration, positive outcome(s) relating
to frailty or aspects of frailty. Methodological quality,
or risk of bias of clinical trials, was calculated by using
a three-item questionnaire, known as the Jadad score
[19]. Drop-outs/withdrawals, randomization, blinding,
and the quality of latter two items are assessed and a
score derived ranging from 0 (very poor) to 5 (rigorous)
[19]. In the assessment of the trials, positive study
outcomes corresponded to at least one primary or sec-
ondary endpoint exposing a significant improvement by
the intervention (i.e., p < 0.05).
Measurement of frailty or aspects of frailty considered
for study selection and data extraction
Measurement of frailty corresponded to highly cited [20] or
other commonly used/recommended (by ADVANTAGE JA)
frailty instruments [5, 14]. The following tools were consid-
ered to be comprehensive frailty scores: (physical) frailty phe-
notype (PFP, also known as Fried Frailty Criteria), Deficit
Accumulation Index (DAI), Frailty index, Electronic Frailty
Index, Gill Frailty Measure, Frailty/Vigor assessment, (The
Rockwood) Clinical Frailty Scale, Brief Frailty Instrument,
Vulnerable Elders Survey (VES-13), Fatigue, Resistance,
Ambulation Illness, Loss of Weight Index (FRAIL Index),
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Inter-Frail, Sherbrooke Postal Questionnaire, Groningen
Frailty Indicator, Study of Osteoporotic Fractures frailty
criteria, Tilburg Frailty Indicator, Edmonton Frailty Scale,
Frail Scale, Short Physical Performance Battery (SPPB),
PRISMA-7, Multidimensional Prognostic Index, Geriatric 8
frailty questionnaire for oncology (G8), Kihon Checklist,
Frailty Risk score, Hospital Frailty Risk Score, and
Winograd Screening Instrument.
The aspects of frailty considered to be relevant included
physical performance/function, body composition, body
weight/weight loss, cognition, exhaustion/fatigue, and muscle
strength. We particularly focused on the following assess-
ments: gait speed, walking speed, activities of daily living
(ADL), instrumental activities of daily living (IADL), Timed




The search yielded 291 studies, of which 255 were excluded at
the abstract level (Fig. 1). The remaining 36 studies were
reviewed in full-text and 11 were excluded based on the
abovementioned criteria from this systematic review, leading
to the selection of 25 articles [18, 21–44]. Finally, only 4 of
the 25 studies measured the frailty status by a ‘comprehen-
sive’ frailty instrument as an endpoint, and the remaining 21
studies detected changes in partial aspect(s) of frailty as an
outcome (Table 1). The total number of study participants,
types of intervention, number of trials with positive out-
come(s), and the number of trials with a Jadad score ≥ 3 (a
trial with a score above 2 is considered to have a high quality
[45]) are provided in Table 1.
Studies including a comprehensive frailty score as an
outcome (n = 4)
In only two out of the four studies [23, 24] with a comprehen-
sive frailty score, a significant improvement of the frailty sta-
tus by a multidisciplinary intervention that included medica-
tion review was demonstrated. Both studies used the Short
Physical Performance Battery (SPPB) as frailty instrument
and applied a multidimensional intervention (Supplementary
Table 1a & 1b). In the study conducted by Romera-Liebana
et al. [23] which recruited frail older persons living in the
community, a 12-week intervention was utilized consisting
of exercise training, intake of high protein nutritional drinks/
supplements, memory training, and medication review. Other
aspects of frailty (handgrip strength, Functional Reach Test,
Unipodal Station Test, and several neuropsychological perfor-
mance tests) were measured or performed in addition to the
SPPB. In this trial, handgrip strength, Functional Reach Test,
and the neuropsychological performance tests improved sig-
nificantly (p < 0.05) in the intervention group as compared to
the control group. However, this study had a Jadad score of 2,
suggesting poor quality. The other study conducted by
Matchar et al. [24] recruited participants who visited an emer-
gency department for a fall-related injury and were discharged
home. A tailored program of physical therapy for 3 months
plus screening and follow-up for vision, polypharmacy, and
environmental hazards for 6 months was employed. With a
Jadad score of 3, the trial was of better quality than the
Romera-Liebana study [23]. SPPB was a secondary outcome
which significantly more deteriorated in the control group as
compared to the intervention group.
The remaining two studies [21, 22] both used the frailty
phenotype (Fried Frailty Criteria) to measure frailty; one study
also used SPPB. The study which used SPPB in addition to
the frailty phenotype was a single-drug intervention in males
(testosterone versus placebo) [21]; the other trial utilized a
multidimensional intervention consisting of comprehensive
geriatric assessment and appropriate intervention by medica-
tion adjustment, exercise instruction, nutrition support, phys-
ical rehabilitation, social worker consultation, and specialty
referral in community-dwelling older persons. These studies
showed no improvement of the comprehensive frailty score. A
significant increase in lean body mass by testosterone was
observed in one study [21]; this trial had a higher Jadad score
as compared to the multi-interventional trial (3 versus 1).
In those 11 studies that included a ‘medication review’ [for
categorization see 46], this was a comprehensive prescription
review in 1 case, an adherence review in 1 case, a clinical
medication review in 7 cases, and others in 2 cases. It was
performed by clinicians with different professional back-
grounds (multidisciplinary in 6 cases, geriatricians only, GPs
only or nurses only in 1 case each) and by physicians and
pharmacists or by pharmacists only in 1 case each. Initial
access to past medical records was provided in five cases
(Supplementary Table 1b).
Studies including an aspect of frailty as an outcome
(n = 21)
The majority (n = 13) of the trials which only addressed single
or multiple aspects of frailty as an endpoint were single-drug
interventions [18, 26, 28, 30, 32, 33, 35–40, 42], and in ten of
these trials, a significant improvement of some aspects of
frailty was demonstrated. Only three trials [32, 38, 39] failed
in this regard. Eight trials on single-drug interventions had a
Jadad score of 3 or more [26, 28, 29, 32, 35, 36, 39, 40].
In only two of the 21 studies which focused on aspects of
frailty, a medication optimization process represented the in-
tervention [27, 28]. These studies showed no impact of the
intervention on the aforementioned aspects of frailty.
4 Eur J Clin Pharmacol (2021) 77:1–12
There were six multi-interventional trials [25, 31, 34, 41,
43, 44] with aspects of frailty as an endpoint; except for [31],
they used medication review/optimization as one part of the
intervention. Only three of them (including ref. 28) showed a
positive impact on some aspects of frailty [25, 34]. However,
the Jadad score was below 3 in three of these studies [31, 43,
44].
Supplementary Table 1a & 1b summarizes the 25 random-
ized trials found in this review and provides relevant details
about these studies including type of study population, inter-
vention, the nature of medication review (if applied), out-
comes, and quality of the trial according to the Jadad score
[19].
An overview of frailty aspects considered in these 25 stud-
ies and the frequency and types of interventions with and
without significantly positive impact on aspect(s) of frailty
are provided in Table 2.
Physical performance was measured in 17 studies and im-
proved in 9 of them:
– in two studies involving complex interventions,
– in one study involving an early switch to oral treatment
with diuretics in patients with heart failure and
– in one study utilizing a home-based support program.
Single-drug interventions with positive impact on physical
performance tested
– alfacalcidol (a vitamin D analog),
– teriparatide (an anabolic parathyroid hormone fragment),
– piroxicam (a nonsteroidal anti-inflammatory drug),
– testosterone (an anabolic steroid) or
– capromorelin (a growth hormone secretagogue).
Four of ten interventional trials on muscle strength (includ-
ing handgrip) showed positive results. In two of these trials, a
complex intervention was evaluated; in two other trials,
alfacalcidol or testosterone was applied in the intervention
group.
Body composition and body weight were positively affect-
ed in six of seven interventional trials measuring these param-
eters. The trials with positive outcomes used single drugs (5)/
nutritional supplementation (1) as intervention. The successful
single drugs were testosterone in three studies and
capromorelin or recombinant human chorionic gonadotropin
in one study each.
Cognition, behavioral disturbances, and/or depressionwere
improved in only 2 of 13 trials. One of these trials utilized a
complex intervention and the other a home-based support
Table 1 Results of the structured comprehensive review on interventional medication optimization or pharmacological intervention and its impact on



















































a The following tools were considered to be comprehensive frailty scores: (Physical) Frailty Phenotype (PFP, also known as Fried Frailty Criteria),
Deficit Accumulation Index (DAI), Frailty index, Electronic Frailty Index, Gill Frailty Measure, Frailty/Vigor assessment, Clinical Frailty Scale, Brief
Frailty Instrument, Vulnerable Elders Survey (VES-13), Fatigue, Resistance, Ambulation Illness, Loss of Weight Index (FRAIL Index), Inter-Frail,
Sherbrooke Postal Questionnaire, Groningen Frailty Indicator, Study of Osteoporotic Fractures frailty criteria, Tilburg Frailty Indicator, Edmonton
Frailty Scale, Frail Scale, Short Physical Performance Battery (SPPB), PRISMA-7, Multidimensional Prognostic Index, Geriatric 8 frailty questionnaire
for oncology (G8), Kihon Checklist, Frailty Risk score, Hospital Frailty Risk Score and Winograd Screening Instrument
b The aspects of frailty considered to be relevant included physical performance/function, body composition, body weight/weight loss, cognition,
exhaustion/fatigue, strength, and memory. We particularly focused on the following assessments: gait speed, walking speed, activities of daily living
(ADL), instrumental activities of daily living (IADL), Timed Up and Go test (TUG), handgrip strength, and Mini Mental State Examination (MMSE)
c The Jadad score which is a scale to assess the methodological quality or risk of bias of clinical trials is calculated by using a three-item questionnaire.
Drop-outs/withdrawals, randomization, blinding, and the quality of latter two items are assessed. The derived score ranges from zero (very poor) to five
(rigorous). Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin
Trials. 1996 Feb;17:1–12
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Table 2 An overview of frailty aspects in the interventional studies included in this review. The types of interventions with positive effects on at least
one aspect of frailty or no impact are described separately









Intervention(s) used in the studies with no
impact (separated by a slash)
Intervention(s) used in the studies with






17 (12) 9 (6) Testosterone/spironolactone/MVP




supplement/medication review + Falls
risk factor assessment + modification and
seated balance exercise training
program/‘half-day Chronic Care Clinics’.
These clinics included an extended visit
with the physician and nurse with a
special focus on chronic disease
management; a pharmacist visit that
aimed at a reduction of polypharmacy
and high-risk medications; and a patient
self-management or support group
Exercise training, intake of high protein
nutritional shakes, memory training, and
medication review/medication review
and optimization of medication use,
improvement of physical fitness, social
skills and nutrition/alfacalcidol/early
switch to oral treatment with
diuretics/teriparatide/coordinated care by
nurses for two intervention groups who
also received either an ‘MD.2
medication-dispensing machine’ or a
medplanner (simple box with separate









review, Falls risk factor assessment,
modification and seated balance exercise
training program
Four component intervention: exercise
training, intake of high protein nutritional
shakes, memory training, and medication
review/medication review and
optimization of medication use,





7 (7) 6 (6) Piroxicam Testosterone in 3 studies/orally active GHS
capromorelin/s.c. recombinant human
chorionic gonadotropin/supplementation





13 (6) 2 (0) Medication review and optimization of
medication use, improvement of physical
fitness, social skills and nutrition/single
Multidisciplinary Multistep Medication
Review (3MR)/early switch to oral
treatment with diuretics/deprescribing




tablets of Chinese herbal
formula/assessment by a nurse on 12
dimensions including drug treatment and
recommendations to participants GPs.
Monthly telephone calls were made by
the nurse to verify if the
recommendations had been
implemented/medication review, Falls
risk factor assessment, modification and
seated balance exercise training
program/‘half-day Chronic Care Clinics’.
These clinics included an extended visit
with the physician and nurse with a
special focus on chronic disease
management; a pharmacist visit that
aimed at a reduction of polypharmacy
and high-risk medications; and a patient
self-management or support group
Exercise training, intake of high protein
nutritional shakes, memory training, and
medication review/coordinated care by
nurses for two intervention groups who
also received either an ‘MD.2
medication-dispensing machine’ or a
medplanner (simple box with separate
compartments for individual medication
times)
ADL/IADL 5 (2) 3 (1) Comprehensive geriatric assessment and
appropriate intervention by medication
adjustment, exercise instruction, nutrition
support, physical rehabilitation, social
Medication review and optimization of
medication use, improvement of physical
fitness, social skills and nutrition/early
switch to oral treatment with
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program. Activities of daily living (ADL) and/or instrumental
activities of daily living (iADL) improved in three out of five
studies. In one of these studies, the early switch to oral di-
uretics in patients with heart failure positively affected the
outcomes and the other two were based on complex interven-
tions. Fatigue was ameliorated by piroxicam, while two other
trials with fatigue as an outcome showed no significant im-
provement. Anorexia was positively influenced by a chemo-
therapy regimen (MVP: mitomycin-C, vinblastine, cisplatin)
as compared to MVC (mitomycin-C, vinblastine, carboplatin)
in patients with advanced non-small cell lung cancer.
Discussion
The present systematic review showed that among the identi-
fied 25 studies, only 2 trials on comprehensive frailty scores
reported positive results though the contribution of medication
review was unclear in a multidimensional approach. In addi-
tion, the studies were heterogeneous regarding the nature of
the medication review used (Supplementary Table 1b)
and, thus, do not allow for identifying the most recom-
mendable type of medication review. In the studies on
frailty aspects, ten single-drug interventions were posi-
tive for physical performance, muscle strength, or body
composition. There were no studies on negative effects
of drugs on frailty. To our knowledge, this is the first
systematic review addressing the impact of drug inter-
ventions on frailty or aspects of frailty.
The association of frailty and drugs has been described
repeatedly in the literature, including a recent review by this
group [5]. As many medications may cause mental/cognitive
and/or physical deterioration, a causal relation between those
drugs and major aspects of frailty is plausible. Such side ef-
fects or adverse effects constitute the most important reasons
to classify them as “potentially inappropriate medications”
(PIMs) in PIM lists like the US Beers criteria [47].
Conversely, medications may positively alter aspects of age-
related frailty such as acetylcholine esterase inhibitors,
angiotensin-converting enzyme (ACE) inhibitors, appetite en-
hancers, or nutritional supplements/vitamins to increase mus-
cle strength, all of which have been shown to elicit effects
principally relevant to frailty. Some of these medications are
positively labeled, i.e., to be encouraged in the FORTA (Fit
fOR The Aged) list (labels A or B [48]), a positive/negative
drug list for age appropriateness of drugs or are recommended
in START criteria [49]. It is obvious that frequent med-
ication reviews (every 3–6 months) addressing over- and
under t rea tment issues are a lways des i rable in
multimorbid older patients to avoid noxious side effects
and to provide chances of positively labeled drugs, apart
from dealing with those aspects of frailty.
Table 2 (continued)









Intervention(s) used in the studies with no
impact (separated by a slash)
Intervention(s) used in the studies with
positive outcome (separated by a slash)
worker consultation, and specialty
referral/MVP regimen
diuretics/high-intensity weight-lifting
exercise and treatment of balance,
osteoporosis, nutrition, vitamin
D + calcium, depression, cognition,
vision, home safety, polypharmacy, hip
protectors, self-efficacy, and social
support
Fatigue 3 (3) 1 (1) Testosterone/Tablets of a Chinese herbal
formula
Piroxicam




3 (1) 2 (1) Assessment by a nurse on 12 dimensions
including drug treatment and
recommendations to participants GPs.
Monthly telephone calls were made by
the nurse to verify if the
recommendations had been implemented
Early switch to oral treatment with
diuretics/high-intensity weight-lifting
exercise and treatment of balance,
osteoporosis, nutrition, vitamin
D + calcium, depression, cognition,
vision, home safety, polypharmacy, hip
protectors, self-efficacy, and social
support
ADL activities of daily living, IADL instrumental activities of daily living, GHS: growth hormone secretagogue, s.c. subcutaneous,MVP mitomycin-C
8 mg/m2 d1, vinblastine 4 mg/m2 d 1–8, cisplatin 100 mg/m2 d1); Mini-Mental State Examination; TUG Timed Up and Go Test, PASE Physical
Activity Scale for the Elderly, SPPB Short Physical Performance Battery, SMAF Functional Autonomy Measurement System, FIM Functional
Independence Measure
a Excluding SPPB and frailty phenotype
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It is clearly important to search for evidence to support
these bi-directional claims of impact of medication on aspects
of frailty. The outcome of this search is, however, very limited
as mentioned above. Thus, the impact of medication review in
general and of specific medication avoidance in particular on
frailty in older people is largely unknown. Randomized con-
trolled trials involving increasing numbers of representative
older people using structured medication reviews or individu-
al drug trials as single interventions for frailty are clearly
needed. A key driver in this regard could be the European
Medicine Agency in that it encourages the use of SPPB or
gait speed as instruments in pre- and post-authorization stud-
ies for medicine registration across all therapeutic areas [50].
The 21 trials on particular aspects of frailty were more
conclusive in that 10 trials with positive outcomes tested
single-drug interventions. The medications with positive ef-
fects on physical performance, muscle strength, body compo-
sition, and fatigue were alfacalcidol, teriparatide, piroxicam,
testosterone, recombinant human chorionic gonadotropin, and
capromorelin. Notably, none of them proved to be beneficial
to improve comprehensive frailty scores. A strong biological
understanding of frailty based on basic research is needed
before more focused and presumably more successful treat-
ment strategies may be developed.
Many of the trials (N = 10) found in this systematic review
are of low methodological quality according to the Jadad
score, a finding that emphasizes the lack of compelling data
and strategies.
It is remarkable that no prospective RCT-derived evidence
was found for the potentially harmful effects of medications on
frailty symptoms. There is abundant literature on potentially
harmful drugs, such as those that predispose to falls, delirium
or dementia, drugs that may even increase mortality (e.g., seda-
tive antihistamines) [51, 52]. However, none of them clearly
describe the worsening of aspects of frailty or the use of a com-
prehensive frailty score according to the criteria of this system-
atic review. For instance, falls are not included in most frailty
concepts, but usually considered as an outcome of frailty.
From the findings of the present systematic review, it ap-
pears that a classic prospective, controlled RCT designed to
examine the harmful effects of medications in age-related
frailty would be ethically questionable as it would involve
placing already incapacitated patients at potentially higher risk
if still exposed to potentially harmful drugs in the control
group. Thus, other trial designs (for example, stepped-wedge
design) and/or other interventions such as re-prescribing (the
replacement of inappropriate medications by better alterna-
tives for the treatment of a given disease, thus reflecting the
combined optimization of both over- and undertreatment is-
sues) based on medication reviews would be more acceptable
from an ethical perspective. As is evident from this systematic
review, such trials should involve singular interventions since
multiple interventions would be difficult to relate to specific
impacts. In addition, to identify culprit drugs, such trials have
to be large enough to provide information on the contribution
of particular drugs or drug classes such as sedatives or antihy-
pertensives on particular elements of the frailty syndrome.
An additional point of attention in designing such trials is
the heterogeneity of frailty definitions and frailty assessment
scores that measure different aspects of frailty in a non-
specific manner. Importantly, a recent review comparing 35
different frailty scores concluded that “research results based
on different frailty scores cannot be compared or pooled” [53].
In this regard, recent efforts have been made in trying to find a
consensus for functional status across available assessments of
physical function or physical frailty [54]. It is also highly
likely that such trials would have to be international, involving
cooperative consortia with considerable public funding.
Clearly, pharmaceutical companies will not be motivated to
funding trials on negative outcomes of certain drugs.
Furthermore, most of those drugs under suspicion in relation
to age-related frailty are generic, further minimizing the level
of interest among pharmaceutical companies in funding RCT
investigation of the kind.
Limitations
This systematic review was restricted to MEDLINE entries
and to prespecified search terms; thus, relevant literature
may have been overlooked. However, the likelihood of miss-
ing relevant trials with only one entry, for example exclusively
reported in EMBASE, was considered to be low as most trials
have multiple citations referring to each other. Unpublished
studies were not searched for, e.g., by contacting study inves-
tigators or sponsors. The interpretation of results was mainly
done by two researchers who may have misinterpreted some
findings. Besides, publication bias might be present, i.e., lack
of publication of trials with neutral or even negative effects on
frailty or frailty components.
Conclusion
In summary, this review shows that there is virtually no pro-
spective evidence for causal pharmacological effects on frailty
with the exception of few trials demonstrating the positive
impact of medications on partial aspects of frailty.
Dedicated, large prospective trials are urgently needed to iden-
tify both the deleterious and/or beneficial effects of drugs on
frailty.
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